NCT03209921

Pharmacokinetic Variability of Daptomycin During Prolonged Therapy for Bone and Joint Infections

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 23 (actual)
• Sponsor: Hospices Civils de Lyon · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Daptomycin is a cyclic lipopeptide that has been proposed as an alternative therapeutic option in patients with prosthetic joint infection caused by Staphylococcus or Enterococcus species in the latest Infectious Diseases Society of America (IDSA) guidelines. The population pharmacokinetics (PK) of daptomycin have been described in various groups of patients in previous publications. However, little information exists on the PK of daptomycin in patients with bone and joint infections (BJI). Also, previous population studies did not investigate daptomycin PK over prolonged therapy, and, to our knowledge, no study has reported the intraindividual PK variability of this drug. The aim of this study is to describe the inter- and intraindividual PK variability of this drug.

Conditions

• Bone and Joint Infection
• Patient Treated by Daptomycin

Timeline

• Start date: 2015-05-01
• Primary completion: 2015-09-01
• Completion: 2015-09-01
• First posted: 2017-07-06
• Last updated: 2017-07-06